HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy rating and announces Price Target of $12.
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy rating and announces Price Target of $12.